What’s Causing RedCloud Stock (RCT) to Decline in Pre-Market Trading Today?

• Investigation Announcement: Purcell & Lefkowitz LLP is investigating Firefly Neuroscience, Inc. to determine if its directors breached fiduciary duties related to recent corporate actions.

• Shareholder Rights: Shareholders of Firefly Neuroscience are encouraged to seek information about their rights and options through the law firm, which offers consultations at no cost.

• Stock Performance: RedCloud Holdings (RCT) experienced a 65% surge in stock price after joining the NVIDIA Connect program, but saw an 11% decline in pre-market trading the following day, indicating potential volatility and short-term hype.

• Partnership Benefits: The partnership with NVIDIA aims to enhance RedCloud's AI-powered trading tools and address a significant inventory gap in the global FMCG market, providing access to valuable AI resources and development support.

Market Overview

• August Performance: The S&P 500 ended August with a 0.6% decline on the last trading day but achieved a 1.9% gain for the month, marking its fourth consecutive monthly increase. The Dow and Nasdaq also saw slight declines, yet year-to-date performance remains strong.
• Inflation Concerns: Elevated inflation, highlighted by a 2.9% core PCE, has created uncertainty regarding the Federal Reserve's timeline for rate cuts, despite optimistic signals from Fed Chair Jerome Powell.

Notable Stock Movements

• Tech Sector Decline: Major tech stocks like Dell, Marvell, and Nvidia experienced declines, while MongoDB and Snowflake reported significant gains driven by strong AI-related earnings.
• Upcoming Reports: Investors are keenly awaiting the upcoming PCE inflation report, which could influence expectations for a September rate cut amidst ongoing inflation and policy uncertainties.

Bullish Highlights

• Defense Stocks Surge: Reports indicate that the Trump administration is considering acquiring stakes in major defense contractors such as Boeing, Lockheed Martin, and Palantir Technologies, with Lockheed earning 97% of its revenue from federal contracts.
• Eli Lilly's Weight-Loss Pill: Eli Lilly's stock rose after announcing Phase 3 trial results for its oral GLP-1 pill, orforglipron, which showed an average weight loss of 10.5% among patients, boosting investor confidence.
• Firefly Neuroscience's AI Platform: Firefly Neuroscience's stock jumped 31% following the launch of its AI-powered EEG platform, which utilizes Nvidia's L40S GPU to enhance brain signal data quality.

Bearish Highlights

• Marvell's Stock Drop: Marvell Technology's stock fell 16% after its Q2 results were overshadowed by disappointing Q3 sales guidance, despite analysts acknowledging long-term potential in AI and optical growth.
• Tesla's Trust Issues: A survey revealed that nearly half of Americans believe Tesla's Full Self-Driving feature should be illegal, with 70% favoring vehicles equipped with both LiDAR and cameras, contrasting with Tesla's camera-only approach.
• Nutanix's Mixed Earnings: Nutanix's shares declined after a strong Q4 earnings report, which included revenue of $653.26 million that exceeded estimates, but investor enthusiasm waned due to concerns over subscription sales and cautious guidance.

Stock Performance Snapshot

• Key Stock Prices:
  • Boeing (BA): $234.28, -0.80%
  • Eli Lilly (LLY): $730.75, -0.16%
  • Marvell (MRVL): $63.00, -18.4%
  • Nvidia (NVDA): $173.67, -3.61%
  • Tesla (TSLA): $333.86, -3.50%

This content was produced with AI assistance and reviewed by Benzinga editors.

• Penny Stocks to Watch: Allarity Therapeutics, Incannex Healthcare Limited, and Firefly Neuroscience are highlighted as penny stocks to monitor on August 28, 2025, based on their Dollar Volume and market activity.

• Allarity Therapeutics Update: The company received Fast Track designation from the FDA for its cancer treatment stenoparib, leading to a significant stock price increase of over 11% and a Dollar Volume of $553.44 million.

• Incannex Healthcare Performance: Despite a nearly 6% drop in stock price with a Dollar Volume of $351.47 million, Incannex previously announced positive Phase 2 trial results for its psilocybin-assisted therapy, which had caused a surge of nearly 26%.

• Firefly Neuroscience Developments: Firefly's stock fell nearly 3% with a Dollar Volume of $226.16 million after launching its new EEG technology platform, CLEAR, which enhances data quality and processing speed for brain health solutions.

• Firefly Neuroscience Launches CLEAR Platform: Firefly Neuroscience's stock rose after the introduction of its CLEAR platform, which enhances EEG data quality using Nvidia’s advanced GPU technology.

• Improved EEG Data Quality: The CLEAR platform addresses issues in EEG recordings caused by muscle activity and environmental factors, providing cleaner data for better diagnosis and treatment of neurological conditions.

• Nvidia's Expanding Role in Healthcare: Nvidia continues to grow in the healthcare sector, with partnerships aimed at improving drug discovery and pharmaceutical research through AI technologies.

• Stock Performance: As of Tuesday, Firefly's stock increased by 31.27%, while Nvidia's stock has risen 34% year-to-date amid a surge in AI-related investments.

• Introduction of the CLEAR Platform: Firefly Neuroscience has launched its new 'CLEAR' platform, a next-generation preprocessing technology designed to enhance the quality of electroencephalogram (EEG) data for better brain health outcomes.

• Improved Data Quality and Processing Speed: The CLEAR platform utilizes advanced signal processing and machine learning techniques, achieving a 60-80% improvement in processing times while ensuring high-quality EEG data free from artifacts.

• Impact on Clinical Insights: By enhancing EEG signal fidelity, the platform enables researchers and clinicians to detect subtle neural biomarkers, which are crucial for diagnosing and monitoring neurological and psychiatric conditions.

• Company's Growth Strategy: Firefly aims to leverage the CLEAR platform as part of its growth strategy, focusing on transforming neuroscience and clinical development through AI-driven insights and supporting pharmaceutical R&D and clinical trials.